Treatment of Prolactinomas in Low-Income Countries

Table 2

Treatment details for microprolactinomas treated with dopamine agonists and macroprolactinomas treated with adjuvant medical therapy following surgery. Remission and relapse rates are presented in the two groups.

	Microprolactinomas	Macroprolactinomas
Bromocriptine; dose (mg)	24/38; 2.5 (2.5–5.0)	13/23; 2.5 (2.5–5.0)	0.596; 0.853
Cabergoline; dose (mg)	14/38; 0.5 (0.5–0.69)	10/23; 0.5 (0.5–1.0)	0.596; 0.123
Surgical remission	—	23% (9/40)
Duration of treatment (months)	25.0 (15.0–87.0)	25.5 (10.0–43.0)	0.404
Long-term remission	68% (26/38)	43% (10/23)	0.122
PRL at the last control	23.1 (12.4–35.8)	32.9 (12.0–70.0)	0.279
Withdrawal of therapy	16/38	3/23	0.022
Normal PRL after withdrawal	15.8% (6/38)	0% (0/3)	0.073